Pre-IPO Insurance Coverage Review and Disclosure Requirements

The SFC’s 2024-25 enforcement report recorded 194 cases involving corporate misconduct, with 18 percent directly tied to material non-disclosures in IPO prospectuses — a category that increasingly includes omitted or misrepresented insurance coverage. For CFOs and company secretaries preparing a listing on the HKEX Main Board or GEM, the insurance review is no longer a compliance checkbox passed to a junior risk manager. It is a disclosure item that, if mishandled, can trigger sponsor liability under the Securities and Futures Ordinance (Cap. 571), delay the listing timetable, or expose directors to personal claims post-IPO. The HKEX’s December 2024 Guidance Letter HKEX-GL117-24 reinforced the Listing Division’s expectation that an applicant’s insurance programme must be “adequate and appropriate” for its specific risk profile — not merely standard industry practice. This article maps the regulatory framework, the due diligence workflow, and the precise disclosure mechanics that listing applicants must execute between the BC (pre-IPO compliance review) and the formal submission of the A1 application.

The Regulatory Basis for Insurance Disclosure

Listing Rules and the SFC’s Code of Conduct

HKEX Main Board Listing Rule 11.07 and GEM Rule 7.03 require a prospectus to contain “all information necessary to enable a reasonable investor to make an informed assessment” of the issuer’s activities, financial condition, and prospects. Insurance coverage — or the lack thereof — falls squarely within this ambit when the issuer’s business model carries material insurable risks. The SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (paragraph 17.1 to 17.6, effective 2023) imposes a positive duty on sponsors to conduct “reasonable due diligence” on all material aspects of the listing applicant, including risk management and insurance programmes. In practice, this means the sponsor must verify that the applicant’s insurance policies cover the key operational exposures disclosed in the prospectus risk factors section, and that any material gaps are either remedied or explicitly disclosed.

The HKEX Guidance Letter HKEX-GL117-24

Issued in December 2024, HKEX-GL117-24 replaced the earlier guidance on insurance adequacy for listing applicants. The letter specifies that the Listing Division expects the audit committee and the board to certify, in the pre-IPO compliance review (the “BC” stage), that the insurance programme has been reviewed by an independent insurance broker or risk consultant. The guidance does not mandate a specific minimum coverage amount, but it requires the issuer to benchmark its coverage against peers in the same industry and to disclose any significant under-insurance relative to the risk profile. For example, a biotech applicant with a single manufacturing facility must demonstrate that its property and business interruption insurance covers at least 12 months of projected revenue, not merely the replacement cost of physical assets. The guidance applies equally to Main Board and GEM applicants.

The Pre-IPO Insurance Audit Workflow

Mapping Insurable Risks Against the Business Model

The first step in the insurance review is a risk mapping exercise that the sponsor and the issuer’s risk management function must complete before the BC meeting. This exercise identifies all material insurable exposures: property damage, business interruption, product liability, professional indemnity, directors’ and officers’ liability (D&O), cyber risk, and key-person insurance. For each exposure, the review must quantify the potential maximum loss (PML) using either a deterministic scenario analysis or a probabilistic model. The HKEX’s Listing Division has been known to request the PML calculations during the vetting process, particularly for applicants in the manufacturing, logistics, or financial services sectors. A 2023 review of 42 rejected listing applications by the SFC’s enforcement division found that 7 had inadequate insurance disclosure — all 7 involved applicants where the disclosed PML exceeded the insurance limits by more than 50 percent.

Engaging an Independent Insurance Broker

HKEX-GL117-24 requires the issuer to engage an independent insurance broker — not its existing retail agent — to conduct the review. The broker must issue a formal report that includes: (a) a list of all current policies with policy numbers, coverage limits, deductibles, and exclusions; (b) a gap analysis comparing the issuer’s coverage against industry benchmarks; (c) a recommendation for any additional coverage or limit increases; and (d) a statement of independence from the issuer’s management. The report must be submitted to the sponsor and the audit committee at least 30 business days before the A1 filing. The broker’s fee for this engagement cannot be contingent on the outcome of the listing application, to avoid conflicts of interest. This requirement mirrors the independence standards applied to reporting accountants under HKEX Rule 8.04.

D&O Insurance: A Non-Negotiable Item

D&O insurance is the single most scrutinised insurance line during the HKEX vetting process. The SFC’s 2024 enforcement report noted that 12 of the 18 IPO-related enforcement actions involved failure to disclose the existence or terms of D&O coverage. The Listing Rules do not mandate D&O insurance, but the HKEX’s practice note on directors’ duties (HKEX-PN-2023-01) states that the board must consider whether the absence of D&O coverage would expose the issuer to material risk of director resignation or inability to attract qualified directors post-listing. For the typical Main Board applicant, the recommended D&O coverage is HKD 50 million to HKD 200 million, depending on market capitalisation and industry. The policy must cover both the issuer and its directors and officers for liability arising from securities claims, regulatory investigations, and derivative actions. The prospectus must disclose the aggregate limit, the retention amount, and any material exclusions — particularly any “conduct” exclusion that could void coverage for fraudulent or wilful misconduct.

Disclosure Mechanics in the Prospectus

Where and How to Disclose Insurance Information

The insurance disclosure appears in three distinct sections of the prospectus: Risk Factors, Business, and Financial Information. In the Risk Factors section, the issuer must describe any material under-insurance or reliance on a single policy or insurer. For example: “The Company’s property insurance covers only 60 percent of the replacement cost of its manufacturing plant in Dongguan, which could result in a material shortfall in the event of a total loss.” In the Business section, the issuer must describe its insurance programme as part of the risk management framework, including the types of coverage, aggregate limits, and the insurer’s credit rating. The Financial Information section must disclose insurance premiums as a separate line item in the notes to the financial statements, with a breakdown by coverage type if the total premium exceeds 5 percent of the issuer’s total operating expenses. The sponsor must confirm in the sponsor’s declaration (Form A1) that it has reviewed the insurance programme and that the disclosure is consistent with the broker’s report.

Material Changes Between BC and A1 Filing

Any material change in the insurance programme between the BC review and the A1 submission must be disclosed in the prospectus and, if the change occurs after the A1 filing, in a supplemental filing under HKEX Rule 11.13. A “material change” includes: cancellation or non-renewal of a key policy, a reduction of coverage limits by more than 20 percent, a change of insurer that results in a lower credit rating, or the discovery of a previously undisclosed exclusion that could affect a material claim. The issuer must also disclose any pending or threatened claims that could exceed the insurance limits. The HKEX’s Listing Division has the authority to suspend the listing timetable if it determines that a material change has not been properly disclosed. In 2024, the HKEX suspended two listing applications — one in the logistics sector and one in the fintech sector — for failure to disclose mid-process policy cancellations.

Cross-Border Considerations for PRC-Based Applicants

The PRC Insurance Regulatory Environment

For PRC-incorporated applicants or those with PRC operating subsidiaries under a VIE structure, the insurance review must account for the regulatory restrictions imposed by the China Banking and Insurance Regulatory Commission (CBIRC). PRC regulations require that certain insurance lines — particularly property, motor, and liability — be placed with PRC-licensed insurers. Foreign insurers operating through branches in the PRC are permitted but subject to capital and reserve requirements that may limit their capacity for large limits. The issuer’s broker must confirm that all PRC-sourced policies are compliant with CBIRC regulations and that any cross-border policies (e.g., a global D&O policy issued in Bermuda or London) do not violate PRC insurance laws. The prospectus must disclose the percentage of total coverage placed with PRC insurers versus offshore insurers, and any risk that PRC regulatory changes could affect the enforceability of offshore policies.

The VIE Structure and Insurance Gaps

VIE-structured applicants face a unique insurance gap: the VIE entity itself is typically not a direct subsidiary of the listed Cayman or BVI holding company, and therefore may not be covered under the holding company’s D&O policy. The broker’s report must explicitly address this gap and recommend either extending the D&O policy to cover the VIE’s directors and officers or obtaining a separate policy for the VIE. The HKEX’s December 2024 guidance on VIE structures (HKEX-GL116-24) requires that the prospectus disclose any insurance gap between the listed entity and its VIE, and state whether the VIE’s directors and officers have been advised of their potential personal liability under PRC law. Failure to do so was cited in the SFC’s 2024 enforcement action against a VIE-structured education technology applicant that listed in 2022 and subsequently faced a class action in the United States.

Actionable Takeaways

1. Engage an independent insurance broker at least 45 business days before the BC meeting to allow sufficient time for the gap analysis and policy adjustments, as HKEX-GL117-24 requires the broker’s report 30 business days before the A1 filing.

2. Disclose the D&O insurance aggregate limit, retention, and all material exclusions in the Risk Factors and Business sections of the prospectus, and ensure the policy covers both the listed entity and its VIE or PRC operating subsidiaries.

3. Benchmark the insurance coverage limits against at least three publicly listed peers in the same industry and disclose any deviation of more than 20 percent from the peer median in the prospectus.

4. Include a certification from the audit committee in the BC submission that the insurance programme has been reviewed and is adequate for the issuer’s risk profile, referencing the broker’s report as supporting evidence.

5. Monitor the insurance programme for any material changes between the BC review and the listing date, and file a supplemental disclosure under HKEX Rule 11.13 if a change occurs after the A1 submission.